Blueprint Medicines Corporation (BPMC) News
Filter BPMC News Items
BPMC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BPMC News Highlights
- BPMC's 30 day story count now stands at 4.
- Over the past 29 days, the trend for BPMC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CELL, DRUG and HR are the most mentioned tickers in articles about BPMC.
Latest BPMC News From Around the Web
Below are the latest news stories about BLUEPRINT MEDICINES CORP that investors may wish to consider to help them evaluate BPMC as an investment opportunity.
Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual MeetingBlueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations showcase the company's progress in developing precision therapies to address the needs of broad patient populations, including hormone-receptor-positive/HER2-negative (HR+/HER2-) breast cancer and EGFR-mutant non-small cell lung cancer (NSCLC). |
NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic MastocytosisBlueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence, a journal from The New England Journal of Medicine Group, has published detailed results from the PIONEER trial of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM). Data reported in the publication show that AYVAKIT achieved statistically significant and clinically meaningful benefits across efficacy measures including disease symptoms and pathological mast cell burden, which continued |
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic MastocytosisBlueprint Medicines Corporation (Nasdaq: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM). All U.S. patients with ISM now have access to the first and only approved medicine designed to treat their disease. |
Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View UpBlueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news. |
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that, effective May 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 18,300 shares of its common stock and an aggregate of 9,146 restricted stock units (RSUs) to eleven new employees under Blueprint Medicines' 2020 Inducement Plan. |
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue EstimatesBlueprint Medicines (BPMC) delivered earnings and revenue surprises of 19.17% and 48.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Blueprint Medicines Reports First Quarter 2023 ResultsBlueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2023. |
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should KnowY-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Analysts Estimate Blueprint Medicines (BPMC) to Report a Decline in Earnings: What to Look Out forBlueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual MeetingBlueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6. The presentations showcase Blueprint Medicines' next wave of therapeutic candidates in its robust clinical pipeline, and highlight ongoing progress as the company seeks to pioneer innovative combination strategies and advance development of its programs |